自身免疫性肝炎患者血清趋化因子和GP73水平变化及其临床意义研究

doi:10.3969/j.issn.1672-5069.2020.06.017

摘要/Abstract

摘要： 目的探讨自身免疫性肝炎(AIH)患者血清趋化因子和高尔基体糖蛋白73(GP73)水平的变化及其临床意义。方法 2018年3月～2019年3月我院就诊的46例自身免疫性肝炎患者和46例同期健康人群,采用ELIS法检测血清趋化因子C-C-基元受体6和20(CCR6、CCL20)、血清趋化因子配体10(CXCL10)和GP73水平。AIH患者接受肝活检,并将肝炎程度分为轻中重度。结果 AIH血清CCR6、CCL20、CXCL10和GP73水平分别为(112.4±59.3)pg/mL、(186.5±71.8)pg/mL、(81.5±42.0)pg/mL和(171.4±62.5)ng/mL,均显著高于健康人【分别为(75.8±32.6)pg/mL、(123.7±42.2)pg/mL、(53.9±28.1)pg/mL和(83.1±35.2)ng/mL,P<0.05】;10例重度患者血清CCR6、CCL20、CXCL10和GP73水平分别为(174.2±81.4)pg/mL、(271.5±99.7)pg/mL、(162.7±83.1)pg/mL和(278.3±91.5)ng/mL,,显著高于14例中度组【分别为(124.5±55.3)pg/mL、(198.6±66.9)pg/mL、(88.4±46.8)pg/mL和(186.2±75.8)ng/mL,P<0.05】或22例轻度组【分别为(83.5±34.5)pg/mL、(155.6±51.0)pg/mL、(42.6±22.7)pg/mL和(123.9±58.9)ng/mL,P<0.05】;26例肝组织G3～4级患者血清CCR6、CCL20、CXCL10和GP73水平分别为(154.5±28.1)pg/mL、(201.6±56.3)pg/mL、(98.4±56.1)pg/mL和(196.2±59.78)ng/mL,显著高于20例G1～2级组【分别为(73.5±34.8)pg/mL、(135.6±41.7)pg/mL、(62.5±20.1)p g/mL和(93.9±33.9)ng/mL,P<0.05】。结论 AIH患者血清CCR6、CCL20、CXCL10和GP73水平升高,且随着疾病程度和肝组织炎症活动度加重而升高。检测自身免疫性肝炎患者血清趋化因子和GP73水平可能有助于评估患者病情的变化。

关键词: 自身免疫性肝炎, 趋化因子C-C-基元受体6, 趋化因子C-C-基元配体20, 趋化因子配体10, 高尔基体糖蛋白73

Abstract: Objective The aim of this study was to investigate the changes of serum chemokines and golgi glycoprotein 73 (GP73) levels in patients with autoimmune hepatitis (AIH) and their clinical significance. Methods 46 patients with AIH and 46 healthy persons were recruited in our hospital between March 2018 and March 2019, and liver biopsies were performed in patients with AIH. The histopathological activities were divided into mild, moderate and severe degrees. Serum chemokine C-C-receptor 6 and 20 (CCR6 and CCL20), chemmokine C-C-ligand 10 (CXCL10) and GP73 levels were detected by ELISA. Results Serum CCR6, CCL20, CXCL10 and GP73 levels in patients with AIH were (112.4±59.3)pg/mL, (186.5±71.8)pg/mL, (81.5±42.0)pg/mL and (171.4±62.5)ng/mL, significantly higher than 【(75.8±32.6)pg/mL,(123.7±42.2)pg/mL, (53.9±28.1)pg/mL and (83.1±35.2)ng/mL, respectively, P<0.05】 in healthy persons; serum CCR6, CCL20, CXCL10 and GP73 levels in 10 patients with severe AIH were (174.2±81.4)pg/mL, (271.5±99.7)pg/mL, (162.7±83.1) pg/mL and (278.3±91.5)ng/mL, all much higher than 【(124.5±55.3)pg/mL,(198.6±66.9)pg/mL,(88.4±46.8)pg/mL and (186.2±75.8)ng/mL, respectively, P<0.05】 in 14 patients with moderate AIH or 【(83.5±34.5)pg/mL, (155.6±51.0)pg/mL,(42.6±22.7)pg/mL and (123.9±58.9)ng/mL, respectively, P<0.05 in 22 patients with mild AIH; serum CCR6, CCL20, CXCL10 and GP73 levels in 26 patients with hepatic G3-4 were (154.5±28.1)pg/mL, (201.6±56.3)pg/mL, (98.4±56.1)pg/mL and (196.2±59.78)ng/mL, all significantly higher than 【(73.5±34.8)pg/mL, (135.6±41.7)pg/mL, (62.5±20.1)pg/mL and (93.9±33.9)ng/mL, respectively, P<0.05】 in 20 patients with hepatic G1-2. Conclusion Serum CCR6, CCL20, CXCL10, and GP73 levels elevates greatly in patients with autoimmune hepatitis, and as the disease deteriorate, they increase obviously. The detection the serum parameters might monitor the illness progress, which needs multi-central investigation.

Key words: Autoimmune hepatitis, Chemokine C-C-motif receptor 6, Chemokine C-C-motif ligand 20, Chemokine ligand 10, Glycosyl glycoprotein 73

凌晶, 张友健, 宋雄峰. 自身免疫性肝炎患者血清趋化因子和GP73水平变化及其临床意义研究[J]. 实用肝脏病杂志, 2020, 23(6): 825-828.

Ling Jing, Zhang Youjian, Song Xiongfeng. Changes of serum chemokines and GP73levels in patients with autoimmune hepatitis[J]. Journal of Practical Hepatology, 2020, 23(6): 825-828.

参考文献

[1] 林兰, 沈敏, 阮健文. 自身免疫性肝炎患者肝组织程序性死亡受体1表达及其临床意义探讨. 实用肝脏病杂志, 2019, 22(2): 204-207.
[2] Kiyoshi M, Yoshiro H, Hideko K, et al.Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis. Medicine, 2018, 97(50): 13450-13451.
[3] Elisabeth S, Robert S, Tanja G, et al. Autoimmune hepatitis-immunologically triggered liver pathogenesis—diagnostic and therapeutic strategies. J Immunol Res, 2019, 3(1): 943-947.
[4] Benkheil M, Van H M, Roskams T, et al. CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): potential role in HCV-related liver cancer. ExpCell Res, 2018, 372(2): 345-360.
[5] Aylin T, Lior H K, Hashem B E, et al. Incidence and determinants of hepatocellular carcinoma inautoimmune hepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol, 2017, 15(8): 1207-1217.
[6] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015年).实用肝脏病杂志, 2015, 24(12): 969-982.
[7] Abdulrahman A A, Badr A J, Ali A, et al. The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis. Saudi J Gastroenterol, 2018, 24(1): 1-20.
[8] Hirayuki E, Shuhei N. Similarities and differences in autoimmune hepatitis epidemiology between east and west: autoimmune hepatitis in East Asia, Southeast Asia, and South Asia. Inflamm Intest Dis, 2017, 1(4): 150-158.
[9] Jayeshbhai C, Hajam I A, Verma A K, et al. Chemokine CCL20 plasmid improves protective efficacy of the montanide is 206 adjuvanted foot-and-mouth disease vaccine in mice model. Vaccine, 2018, 10(1): 3498-3501.
[10] Roongruedee C, Anapat S, Anchalee A, et al. Autoimmune hepatitis in human immunodeficiency virus-infected patients: a case series and review of the literature. World J Gastroenterol, 2019, 25(35): 5388-5402.
[11] 魏梅娟, 张小曼, 许正锯, 等. 慢性乙型肝炎患者抗病毒治疗前高尔基体蛋白73与细胞因子的相关性. 中华实验和临床感染病杂志(电子版), 2017, 11(2): 141-145.
[12] Katrina K A, Peterson N, Truesdell P, et al. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. GynecolOncol, 2017, 145(3): 190-199.
[13] Ranasinghe R, Eri R. Pleiotropic immune functions of chemokine receptor 6 in health and disease. Medicines, 2018, 5(3): 678-691.
[14] Zhao X, Li Y P, Wang X L, et al. Synergistic association of FOXP3⁺ tumor infiltrating lymphocytes with CCL20 expressions with poor prognosis of primary breast cancer: a retrospective cohort study. Medicine, 2019, 98(50): 18403-18404.
[15] Masat E, Laforêt P, Amelin D, et al. Cytokine and chemokine profiling shows rapid activation of the immune system following enzyme replacement therapy in Pompe disease. Neur Dis, 2015, 25(11):378-380.
[16] 彭小燕, 徐莉娟, 刘鹏, 等. 自身免疫性肝炎患者血清腺苷脱氨酶水平与肝组织炎症活动程度的关系及对治疗应答的影响. 实用肝脏病杂志, 2019, 22(2): 200-203.
[17] Hasseldam H, Rasmussen R S, Johansen F F. Oxidative damage and chemokine production dominate days before immune cell infiltration and EAE disease debut. JNeuro Inf, 2016, 13(1): 12-18.
[18] Luana C, Teresa S, Sarah E, et al. Vaccination rate and immunity of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany. Vaccine, 2020, 38(7): 1456-1459.
[19] Lu F B, Chen D Z, Chen L, et al. Attenuation of experimental autoimmune hepatitis in mice with bone mesenchymal stem cell-derived exosomes carrying microrna-223-3p. Mol Cells, 2019, 42(12): 1789-1790.
[20] 刘靓懿, 宿冬远. 药物性肝损伤与自身免疫性肝炎临床和肝组织病理学特征比较研究.实用肝脏病杂志, 2018, 21(3): 463-464.